Liht Cannabis Corp. (CSE: LIHT) (OTCQX: LIHTF) (FSE: 2M0) (“Liht”) or the “Company”) would like to provide supplemental information on how the Company intends to deal with quality assurance and shortages of cannabis in Canada, post-prohibition. Within this news release, the Company will provide our current and prospective shareholders with the steps and measures we will be taking to ensure product quality and cultivation yield.
Liht has researched product quality and yield related issues facing cannabis cultivators to aid in the development of our own methodology of growing organic cannabis that meet patients’ medical needs.
Our facilities are monitored by a series of state-of-the-art computers controlling molecular and environment reading technologies that allow the operators to “communicate” with the plants and control the growing conditions needed for each plant. This reduces the level of human error involved in the growing process.
The Company utilizes a unique lighting technology that encourages the plants own natural chemical resistance to fighting off pests and diseases. This is achieved through the adjustment of the lighting spectrum instead of through the utilization of chemicals. Our “lighting recipe” can be altered to introduce additional specific spectrums which will inhibit the growth of mold and mildew without hindering the plant development.
Through photomorphogenics, a “stage of life” control for plants giving us the ability to differentiate plant “stem cells”’ without the use of chemicals, we will be able to control internodal (branching) spacing and overall structure of the plant. This helps us predict and control the quality of flower, the timing of harvest, the curing process post-harvest, and genetic expressions during growth. The system suppresses negative genes and enhances the environment for positive traits.
Photomorphogenics will work together with a proprietary testing and quality assurance technology known as the S5 Microscopic Spectroscopy Analysis and S5 Biochip technology. The technology is a highly accurate, fully-integrated, non-invasive and non-destructive testing platform providing the highest resolution testing available. Typical testing requires reliance on dead plant matter while the S5 Microscopic Spectroscopy Analysis and Biochip technology tests living material and monitors plant development down to a cellular level.
The technology defines nutrient and hormone needs and the timing of delivery of each, respectively, and alerts operators of any stress in the plant caused by contaminants. This provides early detection of pests, disease or fungus and identifies the perpetrators. The S5 Microscopic Spectroscopy Analysis and S5 Biochip technology will then incorporate interactive mitigation techniques with evidentiary support documenting how and when mitigation of that specific case of pest/disease/fungus was achieved.
We have the ability to identify each plant genetically at a cellular level, allowing incorporation of our proprietary tamper-proof holographic labelling for each plant. As we can monitor from seed to harvest, we will have the ability to identify the most productive plants for cloning which will help us achieve manufacturing of perfected seed cells.
This technology gives us the ability to produce mature plants, shortening cultivation cycles while producing exact replication of successful strains.
In closing, the aforementioned growing methods and technologies help us determine what metrics will provide for consistent and optimum crop quality and yield, early seed germination, earlier crop harvest, increases and escalation of valuable oils, strain purity and optimization of hybrid methods for rapid deployment to harvest. Liht’s growing technologies are not limited to the technologies mentioned in this article and the Company is dedicated to research and ongoing development of its cultivation processes.
“Being an established Industrial Engineer with years of hands on research and development, I have direct access to unique resources and technologies, from technology leaders who have paved the way and have set the standards which all other corporations then follow
My expertise in ago-sciences and the associated technologies allows me to provide Liht with the greatest understanding of how to best apply well suited products, technologies and systems to reduce unnecessary time and resources on trial and error research.
The single greatest advantage in business is having the correct people who are integral to the overall vision and its successful conclusion.” Josef Tyls M.Sc., Ph.D Ind.Eng., Liht Management Advisory Board
ABOUT LIHT CANNABIS CORP.
Liht Cannabis Corp. is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Liht has rapidly expanded to include cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.
FOR FURTHER INFORMATION:
or Linda Sampson, CEO 778-583-4476
Liht trades in Canada, ticker symbol LIHT on the CSE, in the United States, ticker symbol LIHTF on the OTCQX, and in Europe, ticker symbol 2M0 on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.
Neither the CSE nor its Regulation Services Provider, the FSE nor the OTCQX® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQX® accepts responsibility for the adequacy or accuracy of this release.
MARIJUANA INDUSTRY INVOLVEMENT:
Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.
Liht owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Liht’s ability to access private and public capital could be affected and or could not be available to support continuing operations.
Liht’s business is conducted in a manner consistent with state law and is in compliance with licensing requirements.
Copies of licenses are posted on Liht’s website. Liht has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.
FORWARD – LOOKING STATEMENTS:
Certain statements in this release are forward-looking statements, which includes, the effective trading date for the new name and symbol, the expected outcomes of its business, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. Forward-looking statement are necessarily based upon a number of factors that, if untrue, could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements express or implied by such statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, present and future business strategies, the environment in which the Company will operate in the future, and other factors, many of which are beyond the control of the Company. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks.
Forward-looking statements are subject to a variety of risks and uncertainties, which could cause actual events, level of activity, performance or results to differ materially from those reflected in the forward-looking statements, including, without limitation: that laws and regulations may become more onerous; the ability of the Company to obtain necessary financing; the economy generally; the future growth, results of operations, performance and business prospectus and opportunities; changes in and the effect of government policies; demand for products; competition; anticipated and unanticipated costs; reliance on management; claims and legal proceedings; conflicts of interest; and market price and volatility of the Common Shares. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, the loss of key directors, employees, advisors or consultants, technology failures, failure to obtain a license from Health Canada or from other government agencies, failure to develop new and innovative products, failure of counterparties to perform their contractual obligations and fees charged by service providers. Important factors that could cause actual results to differ materially from the Company’s expectations include, litigation, global economic climate, loss of key employees and consultants, additional funding requirements, changes in laws, competition, and failure of counterparties to perform their contractual obligations. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Investors are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above. The Canadian Securities Exchange has not reviewed, nor approved the contents of this news release.